---
title: Association Between Mitochondrial DNA Content and Risk of Gastric Cancer
nct_id: NCT02944539
overall_status: COMPLETED
sponsor: Air Force Military Medical University, China
study_type: OBSERVATIONAL
primary_condition: Stomach Neoplasms
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02944539.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02944539"
ct_last_update_post_date: 2016-10-26
last_seen_at: "2026-05-12T07:13:43.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Association Between Mitochondrial DNA Content and Risk of Gastric Cancer

**NCT ID:** [NCT02944539](https://clinicaltrials.gov/study/NCT02944539)

## Key Facts

- **Status:** COMPLETED
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 600
- **Lead Sponsor:** Air Force Military Medical University, China
- **Conditions:** Stomach Neoplasms
- **Start Date:** 2016-03
- **Completion Date:** 2016-09
- **CT.gov Last Update:** 2016-10-26

## Brief Summary

Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of gastric cancer.The aim of this study was to explore association between mtDNA content in peripheral blood cells could be used as a risk predictor for gastric cancer.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 85 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* 1.histological confirmed gastric adenocarcinoma; 2.receiving surgical resection; 3.no preoperative anticancer treatment; 4.alive at least 1 months after surgery.

Exclusion Criteria:

* 1.history of other malignancy; 2.blood transfusion within one month or prior bone marrow transplantation; 3.patients who reluctant to sign informed consent.
```

## Arms

- **Gastric cancer group** — 300 consecutive patients were recruited, who have diagnosed with gastric cancer by biopsy
- **Control group** — The 300 healthy controls without previous cancer history were recruited from individuals who visited investigator's hospital for physical examination during the same time period as the case enrollment.

## Primary Outcomes

- **Relative copy number of mitochondrial DNA** _(time frame: From date of percutaneous coronary intervention until the date of discharging from hospital, assessed up to 5 days)_ — The ratio of mitochondrial DNA contents to hemoglobin contents was calculated for each sample from standard curves. After that, the ratio for each sample was normalized to a calibrator DNA in order to standardize between different runs, and then defined as the measurement of relative mtDNA contents.Relative expression of mtDNA were measured in patients suffered from gastric cancer when compared with control group.

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02944539.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02944539*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*